Amazing New Canine Cancer Drug

PCI Animal Health is proud to announce we now carry Kinavet-CA1, a tyrosine kinase inhibitor that treats grade II and grade III mast cell tumors.  Kinavet-CA1 is not chemotherapy - it's targeted therapy because of the specificity of its action against a specific receptor found on mast cell tumor cells and other tumor types.  It's also easy to use with tablets given by mouth once a day.

In a phase III clinical study (randomized, double-blind, placebo-controlled) conducted with 202 client-owned dogs, at least 50% of patients treated with Kinavet-CA1 had their tumor decrease in size by half or more during the first 6 months.  The survival rate after 12 months with dogs treated with Kinavet-CA1 was 62% versus 36% for dogs treated with a placebo.  The drug was generally well tolerated with medically manageable side-effects.

As a result of this study and others, Kinavet-CA1 has been conditionally approved by the FDA Center for Veterinary Medicine for certain types of grade II and grade III canine mast cell tumors.  For more information on this remarkable new product, ask your PCI sales rep or visit www.kinavet.com.